• Home
  • About Us
    • About the Foundation
    • Our Board
    • Our Staff
    • Corporate Support
  • Newsroom
    • News Features
    • Video Links
  • Contact
Donate
  • Get Support
    • Support Near You
  • Give Support
    • Donations
    • Bequest Gifting
    • Volunteer
    • Corporate Partnership
  • Neuromuscular Conditions
    • About Muscular Dystrophy
    • Fact Sheets
    • Research
  • NDR Project
  • Latest Press

Author Archives: penehodge

Human muscle stem cells isolated

Leave a reply
This entry was posted in Latest Press on September 27, 2015 by penehodge.

New allied health resource for Charcot-Marie-Tooth disease

Leave a reply
This entry was posted in Latest Press on September 23, 2015 by penehodge.

The drug that could help Aussie boys walk tall

Leave a reply
This entry was posted in Latest Press on September 23, 2015 by penehodge.
  • NDR: MDFA unveils name and logo of Neuromuscular Digital Resource

    Read More
  • NDR: MDF partners with Meerkats to develop Neuromuscular Digital Resource

    Read More
  • NDR: Visioning Workshop Update

    Read More
  • NDR: Online Survey now live!

    Read More
  • NDR: Melbourne Community Consultation

    Read More
  • Human muscle stem cells isolated

    Researchers have successfully isolated human muscle stem cells and shown that the cells could robustly replicate and repair damaged muscles when grafted onto an injured site. Read More
  • New allied health resource for Charcot-Marie-Tooth disease

    A Practice Brief focusing on foot care for people with Charcot-Marie-Tooth disease (CMT) is now available. Read More
  • The drug that could help Aussie boys walk tall

    Australian boys with Duchenne muscular dystrophy (DMD) stand to improve their quality of life if a breakthrough drug gets approved. Read More
  • Most Powerful Arm Wins Australian Design Biennale Award

    The Australian Graphic Design Association (AGDA) handed out its 2014 awards as part of this year's Australian Design Biennale in Hobart last weekend. Read More
  • Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments

    Recently Prosensa provided reports on their financial results for the third quarter ending September 30, 2014 as well as an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and next steps for our follow-on exon skipping compounds for the treatment of Duchenne muscular dystrophy (DMD). Read More
  • Privacy Policy
  • Sitemap
    ▼
    • NDIS
  • Documents System
  • Get Support
    ▼
    • Cough Assist Program

© 2016 Muscular Dystrophy Foundation Australia

  • | Privacy Policy
  • | Sitemap
    • | NDIS
  • | Documents System
  • | Get Support
    • | Cough Assist Program
| Staff Login